Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Lancet Haematol. 2017 Aug 17;4(9):e431–e442. doi: 10.1016/S2352-3026(17)30140-0

Figure 5.

Figure 5

Cumulative incidence risk (CIR) of progressive disease, death, and second primary malignancies (SPMs) by treatment arm. A) The CIR of progressive disease or death from any cause is higher with placebo compared to lenalidomide (p<0·0001). The CIR of developing a SPM is higher with lenalidomide compared with placebo (p=0·0073). B) The CIR of death from any cause is higher with placebo compared with lenalidomide (p<0·0001). C) The CIR of death from myeloma is higher with placebo than with lenalidomide (p<0·0001) while the CIR of death from SPM is higher with lenalidomide than placebo (p=0·031).